ContraFect Corporation (CFRXQ)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ContraFect Corporation (CFRXQ) trades at $0.00 with AI Score 47/100 (Grade C). ContraFect Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening and drug-resistant infectious diseases. Market cap: $107, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for CFRXQ: CFRXQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CFRXQ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CFRXQ: the 1 perspectives are evenly split.
How is this calculated? →ContraFect Corporation (CFRXQ) Healthcare & Pipeline Overview
ContraFect Corporation, now in Chapter 7 liquidation, focused on developing lysins and antibodies to combat drug-resistant infections, including Staphylococcus aureus and Pseudomonas aeruginosa. Its lead candidate, Exebacase, targeted Staphylococcus aureus, while other programs addressed infections related to biofilms and gram-negative pathogens. The company's future is uncertain due to its bankruptcy filing.
What Is the Investment Thesis for CFRXQ?
ContraFect Corporation's Chapter 7 liquidation filing on December 4, 2023, fundamentally alters any prior investment thesis. The company's pipeline, including Exebacase in Phase III trials for Staphylococcus aureus infections and CF-370 in Phase 1 for Pseudomonas aeruginosa, no longer presents a viable investment opportunity. The company's market capitalization of 107 reflects its current state. Any potential value recovery for shareholders is highly speculative and contingent on the bankruptcy proceedings.
Based on FMP financials and quantitative analysis
CFRXQ Key Highlights
- ContraFect Corporation filed for Chapter 7 liquidation on December 4, 2023, effectively halting its operations.
- The company's lead program, Exebacase, was in Phase III clinical trials targeting Staphylococcus aureus infections before the bankruptcy filing.
- ContraFect was developing CF-370, an anti-bacterial therapeutic candidate, in Phase 1 clinical trials for Pseudomonas aeruginosa infections.
- The company's market capitalization is $0.00B, reflecting its current financial distress.
- ContraFect had a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens.
Who Are CFRXQ's Competitors?
CFRXQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| TLX Telix Pharmaceuticals Limited | $12.15 | +2.36% | $4.12B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CFRXQ's Key Strengths?
- Proprietary lysin technology platform.
- Clinical-stage therapeutic candidates targeting drug-resistant infections.
- License agreement with The Rockefeller University.
- Focus on addressing unmet needs in the anti-infectives market.
What Are CFRXQ's Weaknesses?
- Chapter 7 bankruptcy filing.
- Limited financial resources.
- Dependence on external funding.
- High regulatory hurdles for drug approval.
What Are the Key Risks for CFRXQ?
- Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Chapter 7 bankruptcy proceedings.
- Complete loss of investment for shareholders.
- Delisting from the OTC market.
- Legal and regulatory challenges.
- Inability to revive the company's operations.
What Are the Growth Opportunities for CFRXQ?
- Growth opportunity 1: Prior to its bankruptcy, ContraFect aimed to capitalize on the increasing prevalence of antibiotic-resistant infections. The rise of superbugs like MRSA and Pseudomonas aeruginosa presented a significant market opportunity for novel anti-infective therapies. Exebacase, targeting Staphylococcus aureus, had the potential to address a critical unmet need in this area. The global market for antibacterial drugs was projected to reach billions of dollars, offering substantial revenue potential for successful therapies. However, with the company's liquidation, these opportunities are no longer viable.
- Growth opportunity 2: ContraFect's development of CF-370, targeting Pseudomonas aeruginosa infections, represented another potential growth avenue. Pseudomonas aeruginosa is a common cause of hospital-acquired infections, including ventilator-associated pneumonia and bloodstream infections. The market for therapies targeting Pseudomonas aeruginosa is substantial, driven by the increasing incidence of these infections and the limited treatment options available. However, the company's bankruptcy has halted the development of CF-370, eliminating this potential growth opportunity.
- Growth opportunity 3: The company's research into lysins for treating biofilm-related infections in prosthetic joints and indwelling devices offered a unique growth opportunity. Biofilms are notoriously difficult to eradicate with conventional antibiotics, making them a significant challenge in healthcare settings. ContraFect's CF-296, an engineered lysin, had the potential to address this unmet need. The market for therapies targeting biofilm-related infections is growing, driven by the increasing use of medical devices and the aging population. However, the bankruptcy has suspended the development of CF-296.
- Growth opportunity 4: ContraFect's license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens represented a long-term growth opportunity. Gram-negative bacteria are a major cause of antibiotic-resistant infections, and new therapies are urgently needed. This collaboration had the potential to expand ContraFect's pipeline and address a significant unmet need in the anti-infectives market. However, the future of this collaboration is uncertain due to ContraFect's bankruptcy.
- Growth opportunity 5: The exploration of Exebacase for treating persistent bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) in COVID-19 patients presented a potential growth opportunity during the pandemic. COVID-19 patients were at increased risk of secondary bacterial infections, including MRSA bacteremia. Exebacase had the potential to improve outcomes in these patients. However, with the waning of the pandemic and the company's bankruptcy, this opportunity is no longer relevant.
What Opportunities Does CFRXQ Have?
- Potential for licensing or partnering its therapeutic candidates.
- Growing market for anti-infective therapies due to increasing antibiotic resistance.
- Expansion of its pipeline through collaborations and acquisitions.
- Development of novel therapies targeting biofilm-related infections.
What Threats Does CFRXQ Face?
- Competition from larger pharmaceutical companies.
- Failure to obtain regulatory approval for its therapeutic candidates.
- Patent expirations.
- Changes in healthcare regulations.
What Are CFRXQ's Competitive Advantages?
- Proprietary lysin technology platform for developing novel anti-infective therapies.
- Patent protection for its lead therapeutic candidates, including Exebacase and CF-370.
- Clinical data supporting the efficacy and safety of its therapeutic candidates.
What Does CFRXQ Do?
ContraFect Corporation, established in 2008 and headquartered in Yonkers, New York, was a clinical-stage biotechnology company dedicated to discovering and developing therapeutic protein and antibody products aimed at treating life-threatening and drug-resistant infectious diseases. The company's primary focus was on addressing critical unmet needs in the treatment of severe infections, particularly those caused by antibiotic-resistant bacteria. Its lead program, Exebacase, a novel lysin, had reached Phase III clinical trials and was designed to target Staphylococcus aureus, a common cause of serious infections. In addition to Exebacase, ContraFect was also developing CF-370, an investigational anti-bacterial therapeutic candidate in Phase 1 clinical trials, intended to treat Pseudomonas aeruginosa infections, including ventilator-associated pneumonia, bloodstream infections, complicated urinary tract infections, and surgical site infections. The company also had CF-296 in preclinical development, targeting osteomyelitis and prosthetic joint infections (PJI). Furthermore, ContraFect explored the use of Exebacase for treating persistent bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) in COVID-19 patients. ContraFect's approach involved the development of engineered lysins, such as CF-296, to combat invasive infections caused by Staphylococcus aureus, including biofilm-related infections associated with prosthetic joints, indwelling devices, and osteomyelitis. The company also held a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. However, on December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware, casting doubt on the future of its programs.
What Products and Services Does CFRXQ Offer?
- Discovered and developed therapeutic protein and antibody products.
- Focused on treating life-threatening and drug-resistant infectious diseases.
- Developed Exebacase, a lysin in Phase III clinical trials for Staphylococcus aureus infections.
- Developed CF-370, an investigational anti-bacterial therapeutic candidate in Phase 1 clinical trials for Pseudomonas aeruginosa infections.
- Developed CF-296 for osteomyelitis and prosthetic joint infections (PJI).
- Explored Exebacase for treating persistent bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) in COVID-19 patients.
- Developed engineered lysins for treating invasive infections caused by Staphylococcus aureus, including biofilm-related infections.
- Maintained a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens.
How Does CFRXQ Make Money?
- Focused on discovering and developing novel anti-infective therapies.
- Out-licensed or partnered its therapeutic candidates with larger pharmaceutical companies for commercialization.
- Relied on venture capital and public offerings to fund its research and development activities.
What Industry Does CFRXQ Operate In?
ContraFect Corporation operated within the biotechnology industry, which is characterized by high risk and high reward. Companies in this sector focus on developing innovative therapies for various diseases. The competitive landscape is intense, with numerous companies vying for market share. ContraFect's focus on anti-infectives, particularly lysins, placed it in a niche segment of the broader biotechnology market. However, the company's bankruptcy underscores the challenges faced by smaller biotech firms in securing funding and navigating the regulatory approval process. The bankruptcy of ContraFect highlights the volatility and risk inherent in the biotechnology industry.
Who Are CFRXQ's Key Customers?
- Hospitals and healthcare providers treating patients with severe bacterial infections.
- Patients suffering from life-threatening and drug-resistant infections.
- Pharmaceutical companies seeking to expand their anti-infective portfolios through licensing or partnerships.
Company Profile
ContraFect Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Yonkers, US. CFRXQ has traded publicly since 2014.
ContraFect Corporation (CFRXQ) Valuation Context
Valued at 107, CFRXQ is classified as a micro-cap stock. Relative to its peer group, CFRXQ's quantitative score of 47/100 is below the peer average of 76/100.
F-Score 0/9Financial Health
ContraFect Corporation's Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
FY2026 estForward Outlook
Wall Street analysts project ContraFect Corporation revenue of about $36.0M for fiscal 2026, with EPS near $-2.14.
CFRXQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- ContraFect's recent restructuring might signal a strategic pivot, potentially attracting new investors looking for turnaround stories. Think Chrysler's revival after its government bailout – a new direction can sometimes spark significant interest.
- Despite the bankruptcy, there's still lingering hope in the community regarding their anti-infective platform, suggesting some believe the core technology holds value. This is similar to how some investors held onto Blockbuster stock believing in the brand even during its decline.
- Insider buying activity, even if minimal, can be interpreted as a sign of confidence from within the company. It's a small spark, but it can fuel optimism among retail investors, like Elon Musk buying Tesla shares.
- The company's focus on addressing unmet needs in infectious diseases could resonate with investors seeking socially responsible investments. This is akin to the early enthusiasm around renewable energy companies.
Bear Case
- Bankruptcy filing usually signals severe financial distress, making investors wary of further losses. It's like Lehman Brothers – the bankruptcy itself is a major red flag.
- Community sentiment is largely negative, reflecting concerns about the company's ability to recover from its current situation. This is similar to the widespread pessimism surrounding Enron before its collapse.
- The delisting from major exchanges will likely reduce liquidity and accessibility for investors, exacerbating the downward pressure. It's like a small-cap stock struggling to gain visibility.
- The company's pipeline faces significant uncertainty, with no guarantee of successful product development or commercialization. This is akin to a biotech company with a promising drug that fails in clinical trials.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CFRXQ Latest News
No recent news available for CFRXQ.
CFRXQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CFRXQ.
Price Targets
Wall Street price target analysis for CFRXQ.
CFRXQ MoonshotScore
What does this score mean?
The MoonshotScore rates CFRXQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
CFRXQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that ContraFect Corporation's stock did not meet the requirements for the higher tiers (OTCQX and OTCQB). Companies in this tier often have limited financial disclosure, may be undergoing financial distress (as is the case with ContraFect's Chapter 7 filing), and may not be current in their reporting obligations. Investing in OTC Other stocks carries significant risks due to the lack of regulation and transparency compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- High risk of fraud and manipulation.
- Illiquidity and difficulty in trading shares.
- Potential for delisting and loss of investment.
- Bankruptcy proceedings and uncertain future.
- Verify the company's financial statements, if available.
- Research the company's management team and their track record.
- Assess the company's legal and regulatory compliance.
- Understand the company's business model and competitive landscape.
- Evaluate the company's risk factors and potential liabilities.
- Consult with a financial advisor before investing.
- Be aware of the risks associated with OTC investments.
- Prior history as a NASDAQ-listed company (before delisting).
- Development of therapeutic candidates in clinical trials.
- License agreement with The Rockefeller University.
- Focus on addressing unmet needs in the anti-infectives market.
Common Questions About CFRXQ (Healthcare)
What does ContraFect Corporation do?
ContraFect Corporation was a clinical-stage biotechnology company focused on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases. Its primary focus was on developing lysins, such as Exebacase, to target bacteria like Staphylococcus aureus. However, the company filed for Chapter 7 liquidation in December 2023, halting its operations and development programs. The company's assets are now subject to the bankruptcy proceedings.
What do analysts say about CFRXQ stock?
Given ContraFect Corporation's Chapter 7 bankruptcy filing, there is currently no active analyst coverage or consensus on the stock. The company's financial distress and liquidation proceedings render traditional valuation metrics and growth considerations irrelevant. Any prior analyst ratings or price targets are no longer applicable. Investors should be aware that the stock is highly speculative and carries a significant risk of complete loss of investment.
What are the main risks for CFRXQ?
The primary risk for CFRXQ is the ongoing Chapter 7 bankruptcy proceedings, which pose a significant threat to shareholders. The company's assets are being liquidated, and there is a high probability that shareholders will experience a complete loss of their investment. Additional risks include delisting from the OTC market, potential legal and regulatory challenges, and the inability to revive the company's operations. Investors should exercise extreme caution and be fully aware of the risks associated with investing in a bankrupt company.
What are the key factors to evaluate for CFRXQ?
ContraFect Corporation (CFRXQ) holds an AI score of 47/100 (low). Not financial advice.
How frequently does CFRXQ data refresh on this page?
CFRXQ prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CFRXQ's recent stock price performance?
ContraFect Corporation (CFRXQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary lysin technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CFRXQ overvalued or undervalued right now?
Valuing ContraFect Corporation (CFRXQ) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CFRXQ?
Before investing in ContraFect Corporation (CFRXQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change due to the bankruptcy proceedings.
- The company's future is highly uncertain.